The global Antibody Drug Conjugates (ADC) market is experiencing rapid growth, driven by advancements in cancer therapy and the expanding potential of these targeted treatments. ADCs combine the specificity of monoclonal antibodies with the cytotoxic power of chemotherapy drugs, enabling more precise and effective treatments for various cancers. Antibody Drug Conjugates are a class of biopharmaceutical drugs designed to target and treat cancer cells.